Case Report: Cadonilimab-Induced Multiorgan Immune-Related Adverse Events and Rechallenge

One detailed clinical case report documents a 70-year-old female patient with stage IVB gastric-type endocervical adenocarcinoma. The report describes sequential immune-related adverse events (cystitis, adrenal insufficiency, diabetic ketoacidosis) following cadonilimab therapy and a subsequent successful rechallenge. It was authored by Zhan Peng and last updated on May 20, 2026.

Use Cases

• Study the timeline and management of sequential multiorgan immune-related adverse events based on the detailed case narrative.
• Analyze the feasibility and outcomes of immunotherapy rechallenge after severe adverse events based on the reported 17-month progression-free survival.
• Investigate rare toxicities associated with bispecific PD-1/CTLA-4 inhibitors like cadonilimab based on the documented cases of cystitis, adrenal insufficiency, and diabetic ketoacidosis.

Strengths

• Detailed longitudinal case report spanning a documented 17-month progression-free survival period.
• Includes specific clinical data points such as adverse event grades, treatment dates (e.g., August 16, 2025), and number of therapy cycles (24).
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a single case report (472.7 KB), representing a very limited scope.

Provenance

Source

figshare

Collection Method

Likely a single, detailed clinical case study authored by a medical professional.

Freshness

Last updated 2026-05-20 05:46:08; freshness should be verified.